WAVEMAN · COMPANY

ONT · Onterris, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

ONT

Name: Onterris, Inc. (ONT) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Onterris, Inc.

PHARMA & BIOTECH · SERVICES-MANAGEMENT CONSULTING SERVICES · CIK 0001643615

C-SUITE BUYING · 1☆ WATCH

INSIDER NET · 180D

$610.0K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+19.3%

XBRL, annual

NET MARGIN

-0.1%

CONVERSIONS · 180D

codes C/M, not in net · $164.9K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$610.0K over 180 days

more than 86% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

fewer than five institutions report holding it

REVENUE

+19.3% year over year

more than 68% of Pharma & Biotech

MARGIN

-0.1% net margin

more than 66% of Pharma & Biotech

BUYBACKS

$30.0M repurchased, FY to 2026-06-30

below 54% of Pharma & Biotech

SHORT

11.8% of shares outstanding short · 9.0 days to cover · settled 2026-07-31

more than 83% of Pharma & Biotech

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -42.7%

-42.7%12M

INSIDER BUY

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders are net buyers of their own stock.

The record shows a net $610.0K bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Onterris, Inc. insiders bought a net $610.0K of stock across 3 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

GRAHAM PETER

Director

BUY

2026-06-05

25,140.0

$432.2K

GRAHAM PETER

Director

BUY

2026-06-03

4,860.0

$77.5K

Dicks Allan

Chief Financial Officer

BUY

2026-05-11

6,535.0

$100.4K

3 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Executive pay vs shareholder return

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$3.1M

$7.6M

$1.3M

-20%

+100%

2024

$2.2M

-$8.5M

$986.5K

-40%

+68%

2023

$1.9M

-$35.6M

$924.5K

+4%

+36%

2022

$2.0M

-$33.6M

$1.1M

+43%

+5%

2021

$58.4M

$78.9M

$21.6M

+128%

+32%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$830.5M	$696.4M	$624.2M	$544.4M
OPERATING INCOME	$11.7M	$-36.7M	$-28.4M	$-28.0M
NET INCOME	$-843.0K	$-62.3M	$-30.9M	$-31.8M
EPS (DILUTED)	-0.14	-2.22	-1.57	-1.62
OPERATING CASH FLOW	$107.5M	$22.2M	$56.0M	$20.6M
CASH	$11.2M	$12.9M	$23.2M	$89.8M
LONG-TERM DEBT	$277.1M	$204.8M	$149.0M	$152.5M
DIVIDENDS PAID	$4.2M	$11.1M	$16.4M	$16.4M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE